Text-only version of this email
Quince Therapeutics
November 11, 2024 4:05 PM ESTQuince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child
Neurology Society Annual Meeting
View this release →
Or click here to view all releases.
Show all